Galectin Therapeutics Inc
GALT
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
9
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.60 | 16.00 | -0.18% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,617.44 | 109.17 | 0.21% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 24,681.10 | 340.37 | 1.40% |
| NASDAQ | 26,211.48 | 104.47 | 0.40% |
| Nikkei 225 | 68,751.51 | 1,008.01 | 1.49% |
| NZX 50 Index | 13,635.07 | 16.15 | -0.12% |
| S&P 500 | 7,561.67 | 18.08 | 0.24% |
| S&P/ASX 200 | 8,841.10 | 15.90 | -0.18% |
| SSE Composite Index | 3,955.58 | 11.55 | -0.29% |